| Name | DN-1289 |
| Description | DN-1289 is an orally available, blood-brain barrier-crossing, selective and potent inhibitor with an IC50 value of 17 nM for di-leucine zipper kinase (DLK) and 40 nM for leucine zipper-bearing kinase (LZK).DN-1289 significantly inhibited optic nerve crush (ONC)-induced p-c-Jun in a mouse model. |
| In vitro | DN-1289 (Compound 14) (0.1, 0.3, and 1 μM; 0-20 h) can block the neurite degeneration induced by nerve growth factor (NGF) withdrawal in dorsal root ganglion (DRG) neurons[1]. DN-1289 (0.1, 0.3, and 1 μM; 0-20 h) inhibits the activation of caspases, apoptotic protease, in NGF withdrawal-induced apoptosis in DRG neurons[1]. |
| In vivo | DN-1289 (Compound 14) demonstrates good tolerance in a mouse model at doses of 100 mg/kg and 150 mg/kg administered via intraperitoneal injection once daily for 10-15 days[1]. DN-1289 (150 mg/kg; oral administration; twice daily for 10 days) inhibits c-Jun phosphorylation in the acute optic nerve crush (ONC) injury model[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 55 mg/mL (124.61 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.53 mM), Sonication is recommended.
|
| Keywords | DNAAlkylation | DNA Alkylation | DLK |
| Inhibitors Related | Streptozotocin | Astragaloside IV | Berberine hydrogen sulphate | Chloranil | (-)-Bornyl acetate | Benzbromarone | Anisomycin | Chloramphenicol | Methyl methanesulfonate | Metacetamol | Berberine sulfate | Benzyl salicylate |
| Related Compound Libraries | DNA Damage & Repair Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | CNS-Penetrant Compound Library | Inhibitor Library | Orally Active Compound Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Cancer Compound Library | MAPK Inhibitor Library |
United States
